![]() |
市场调查报告书
商品编码
1880505
尿路动力学设备及耗材市场预测至2032年:依产品类型、技术、应用、最终用户及地区分類的全球分析Urodynamic Equipment and Consumables Market Forecasts to 2032 - Global Analysis By Product Type (Urodynamic Equipment, Urodynamic Consumables, and Other Product Types), Technology, Application, End User and By Geography |
||||||
根据 Stratistics MRC 的一项研究,全球尿路动力学设备和耗材市场预计在 2025 年达到 3.9933 亿美元,预计到 2032 年将达到 7.2532 亿美元,在预测期内复合年增长率为 8.9%。
尿路动力学设备及耗材包括一系列诊断仪器和一次性用品,用于评估膀胱和尿道储存和排放的功能。这些系统可收集尿流率、内部压力和肌肉反应等关键测量数据,以识别尿失禁、尿路阻塞和神经系统相关膀胱疾病等病症。核心仪器包括流量计、压力测量单元、导管和分析软体,而耗材包括一次性导管、电极、导尿管和用于确保检测可靠性和卫生性的无菌组件。
根据美国国立卫生研究院 (NIH) 的数据,到 2023 年,美国将有约 2,500 万成年人患有尿失禁,其中 65 岁及以上人群的盛行率约为 33%。
高龄化社会的发展
与老龄化相关的疾病,例如尿失禁、膀胱功能障碍和前列腺疾病,发病率不断上升,因此需要更先进的诊断工具。医院和诊所越来越多地采用尿路动力学设备来有效管理这些慢性泌尿系统疾病。对早期发现和预防性护理的日益重视也推动了这些设备的普及。诊断准确性的技术进步正在改善患者的治疗效果并减少併发症。随着全球预期寿命的延长,人口老化仍然是市场扩张的主要驱动力。
院内感染(HAI)的风险
使用导管和诊断探针的操作本身就存在交叉感染的风险。医疗专业人员必须遵守严格的感染控制通讯协定,这可能导致设备使用率降低和营运成本增加。监管机构制定了严格的消毒和卫生标准,进一步增加了临床工作流程的复杂性。由于资源和专业知识有限,小规模的医疗机构往往难以达到合规要求。这些与感染相关的担忧会阻碍某些地区的市场渗透速度。
先进技术的融合
人工智慧驱动的诊断平台正在提高膀胱功能分析的准确性,并减少人为误差。云端基础的数据管理系统使医生能够远端监测患者的病情进展,并简化工作流程。携带式和无线设备的普及使得在门诊和居家照护环境中进行检测成为可能。感测器技术的进步和微创设计的改进正在提高患者的舒适度和手术效率。这些创新正在共同重塑市场格局,并为永续成长铺路。
其他诊断方法
超音波和磁振造影等影像技术正日益广泛地应用于膀胱和泌尿道的评估。非侵入性穿戴装置作为一种替代方案正在兴起,无需临床干预即可提供持续监测。这些替代方案往往更受寻求微创解决方案的患者青睐。随着技术的进步,传统的动态检查工具正日益受到新型诊断方法的挑战。若缺乏差异化和创新,传统设备将面临市场份额被这些新兴技术蚕食的风险。
由于择期诊断程序的推迟,新冠肺炎疫情扰乱了尿路动力学设备和耗材市场。医院优先保障加护治疗,减少了常规泌尿系统检查的需求。然而,疫情也加速了数位化进程,远距泌尿系统会诊和远端监测变得普遍。紧急监管核准使得关键诊断工具得以快速部署。疫情后的策略强调韧性、自动化和分散式检查,以应对未来的挑战。
预计在预测期内,尿动力学检测设备细分市场将占据最大的市场份额。
由于尿路动力学设备在诊断复杂泌尿系统疾病方面发挥核心作用,预计在预测期内,该细分市场将占据最大的市场份额。这些设备对于评估膀胱内压、尿流率和括约肌功能至关重要。医院和专科诊所高度依赖基于设备的诊断来指南治疗决策。无线尿流率测定和自动压力感测器等技术进步提高了诊断的准确性和效率。人们对泌尿系统健康的日益重视以及患者数量的增长进一步推动了市场需求。
预计在预测期内,门诊手术中心细分市场将呈现最高的复合年增长率。
由于成本效益高且方便患者,预计在预测期内,门诊手术中心领域将达到最高成长率。门诊手术中心越来越多地采用携带式尿动力学系统,以便在传统医院环境之外进行诊断。优惠的报销政策鼓励门诊检查,从而减轻了大型医疗机构的负担。云端基础的监控和库存管理系统正在提高这些中心的营运效率。随着医疗保健分散化趋势的日益增长,门诊手术中心正成为泌尿系统诊断的重要枢纽。
预计亚太地区将在预测期内占据最大的市场份额,这主要得益于医疗基础设施的持续改善和泌尿系统疾病发病率的上升。中国、印度和日本等国家正在大力投资,以实现诊断技术和医疗设备製造的现代化。政府主导的措施正在促进本地生产,降低对进口的依赖。人工智慧辅助诊断和微创检测的快速普及正在推动该地区的成长。全球製造商与本地分销商之间的合作正在提高医疗服务的可近性和可负担性。
在预测期内,北美地区预计将实现最高的复合年增长率,这主要得益于其技术领先地位和强大的研发生态系统。美国和加拿大在智慧诊断系统和人工智慧驱动的泌尿系统平台方面处于创新主导。监管机构正在简化核准流程,从而加快先进设备的商业化进程。医院正在整合物联网和数据分析技术,以优化诊断工作流程和病患管理。健全的报销机制也为微创诊断技术的广泛应用提供了支持。
According to Stratistics MRC, the Global Urodynamic Equipment and Consumables Market is accounted for $399.33 million in 2025 and is expected to reach $725.32 million by 2032 growing at a CAGR of 8.9% during the forecast period. Urodynamic equipment and consumables encompass a range of diagnostic devices and disposable supplies used to assess how the bladder and urethra store and release urine. These systems capture key measurements like flow rate, internal pressures, and muscular responses to identify disorders including urinary incontinence, blockages, and nerve-related bladder issues. Core devices include flowmeters, pressure measurement units, catheters, and analysis software, while consumables consist of single-use tubing, electrodes, catheters, and sterile components essential for reliable and hygienic tests.
According to the National Institutes of Health (NIH), urinary incontinence affects approximately 25 million adults in the U.S. in 2023, with nearly 33% of people aged 65 and above experiencing this condition.
Rising geriatric population
Age-related conditions such as urinary incontinence, bladder dysfunction, and prostate disorders are becoming more prevalent, requiring advanced diagnostic tools. Hospitals and clinics are increasingly adopting urodynamic testing to manage these chronic urological issues effectively. The growing emphasis on early detection and preventive care is further accelerating equipment utilization. Technological improvements in diagnostic precision are enhancing patient outcomes and reducing complications. As longevity increases worldwide, the geriatric demographic remains a primary driver of market expansion.
Risk of hospital-acquired infections (HAIs)
Procedures involving catheters and diagnostic probes carry inherent risks of cross-contamination. Healthcare providers face strict infection control protocols, which can slow down equipment usage and increase operational costs. Regulatory agencies are imposing stringent sterilization and hygiene standards, adding complexity to clinical workflows. Smaller facilities often struggle to maintain compliance due to limited resources and expertise. These infection-related concerns act as a restraint, limiting the pace of market penetration in certain regions.
Integration of advanced technologies
AI-driven diagnostic platforms are improving accuracy in bladder function analysis and reducing human error. Cloud-based data management systems allow physicians to monitor patient outcomes remotely and streamline workflows. Portable and wireless devices are gaining traction, enabling testing in ambulatory and home-care settings. Advances in sensor technology and minimally invasive designs are enhancing patient comfort and procedural efficiency. Together, these innovations are reshaping the market landscape and creating avenues for sustainable growth.
Alternative diagnostic methods
Imaging techniques such as ultrasound and MRI are increasingly used to assess bladder and urinary tract conditions. Non-invasive wearable devices are emerging as substitutes, offering continuous monitoring without clinical intervention. These alternatives often appeal to patients seeking less invasive solutions. As technology evolves, competition between traditional urodynamic tools and newer diagnostic methods is intensifying. Without differentiation and innovation, conventional equipment risks losing market share to these emerging modalities.
The COVID-19 pandemic disrupted the urodynamic equipment and consumables market by delaying elective diagnostic procedures. Hospitals prioritized critical care, leading to reduced demand for routine urological testing. However, the crisis accelerated digital adoption, with tele-urology and remote monitoring gaining traction. Emergency regulatory approvals facilitated faster deployment of essential diagnostic tools. Post-pandemic strategies now emphasize resilience, automation, and decentralized testing to safeguard against future disruptions.
The urodynamic equipment segment is expected to be the largest during the forecast period
The urodynamic equipment segment is expected to account for the largest market share during the forecast period, due to its central role in diagnosing complex urinary disorders. These devices are essential for evaluating bladder pressure, urine flow, and sphincter function. Hospitals and specialized clinics rely heavily on equipment-based diagnostics to guide treatment decisions. Technological advancements such as wireless uroflowmetry and automated pressure transducers are improving accuracy and efficiency. Rising awareness of urinary health and increasing patient visits are further driving demand.
The ambulatory surgical centers segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the ambulatory surgical centers segment is predicted to witness the highest growth rate, driven by cost-effectiveness and patient convenience. ASCs are increasingly adopting portable urodynamic systems to perform diagnostics outside traditional hospital environments. Favorable reimbursement policies are encouraging outpatient testing, reducing the burden on large healthcare facilities. Cloud-based monitoring and inventory systems are enhancing operational efficiency in these centers. The growing trend of decentralized care is positioning ASCs as vital hubs for urological diagnostics.
During the forecast period, the Asia Pacific region is expected to hold the largest market share, supported by expanding healthcare infrastructure and rising urological disease prevalence. Countries such as China, India, and Japan are investing heavily in diagnostic modernization and medical device manufacturing. Government initiatives are promoting local production and reducing reliance on imports. Rapid adoption of AI-assisted diagnostics and minimally invasive testing is strengthening regional growth. Collaborations between global manufacturers and local distributors are improving accessibility and affordability.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to its technological leadership and strong R&D ecosystem. The U.S. and Canada are pioneering innovations in smart diagnostic systems and AI-driven urology platforms. Regulatory bodies are streamlining approval pathways, enabling faster commercialization of advanced devices. Hospitals are integrating IoT and data analytics to optimize diagnostic workflows and patient management. A robust reimbursement framework supports widespread adoption of minimally invasive diagnostics.
Key players in the market
Some of the key players in Urodynamic Equipment and Consumables Market include Laborie, Teleflex, Natus, Olympus Corporation, MMT / Medkonsult, TIC Medizintechnik, The Prometheus Group, Wellspect Healthcare, SRS Medical, Cook Medical, Santron Meditronic, Medtronic, Verathon, Boston Scientific, and Coloplast.
In October 2025, Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Nalu Medical, Inc., a privately held medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic pain.
In July 2025, Verathon announces the launch of GlideScope(R) ClearFit(TM), a cover-based video laryngoscope designed to deliver airway management capabilities with cost efficiency. ClearFit combines one reusable video baton with an industry-leading selection of six single-use covers, including Mac, Miller, and Hyperangle style options, to address a wide range of patient types and clinical settings.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.